MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021

Rhea-AI Summary

MaxCyte, a leader in cell-engineering technologies, will release its second-quarter financial results on September 13, 2021, after the U.S. market closes. The company will host a conference call at 4:30 p.m. ET to discuss the results. MaxCyte serves numerous biopharmaceutical companies, including 20 of the top 25 by global revenue, and has granted 14 strategic platform licenses for over 75 clinical programs. The conference call will be accessible via a dedicated phone line and webcast.

Positive

• Partnership with 20 of the top 25 biopharmaceutical companies indicates strong market presence.
• 14 strategic platform licenses granted for over 75 clinical programs demonstrates robust business development.

Negative

• None.

GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13^th, 2021. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Conference Call Details

Interested parties may access the live teleconference by dialing (844) 679-0933 for domestic callers or (918) 922-6914 for international callers, followed by Conference ID: 3199124. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

MaxCyte Contacts:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer	+1 301-944-1660
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	+44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited James Black / Duncan Monteith / Matthew O’Dowd	+44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams	+44 (0) 20 7710 7600
UK IR Adviser
Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	+44 (0)203 709 5700 maxcyte@consilium-comms.com
US IR Adviser Gilmartin Group David Deuchler, CFA	+1 415-937-5400 ir@maxcyte.com
US Media Relations Jamie Lacey-Moreira PressComm PR, LLC	+1 410 299-3310 jamielacey@presscommpr.com

FAQ

When will MaxCyte release its financial results?

MaxCyte will release its financial results for Q2 2021 on September 13, 2021.

What is the time of MaxCyte's Q2 2021 financial results conference call?

The conference call will take place at 4:30 p.m. Eastern Time on September 13, 2021.

How can I access the MaxCyte Q2 2021 conference call?

You can access the call by dialing (844) 679-0933 for domestic or (918) 922-6914 for international callers.

What companies does MaxCyte collaborate with?

MaxCyte collaborates with 20 of the top 25 biopharmaceutical companies based on 2020 global revenue.